AG
CDTX

Artal Group’s Cidara Therapeutics CDTX Stock Holding History

Artal Group’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-11,234
Closed -$170K – 124
2022
Q4 		$170K Hold
11,234
– – 0.01% 126
2022
Q3 		$141K Hold
11,234
– – 0.01% 134
2022
Q2 		$110K Hold
11,234
– – 0.01% 133
2022
Q1 		$187K Hold
11,234
– – 0.01% 137
2021
Q4 		$285K Hold
11,234
– – 0.01% 149
2021
Q3 		$503K Hold
11,234
– – 0.01% 144
2021
Q2 		$454K Hold
11,234
– – 0.01% 144
2021
Q1 		$598K Hold
11,234
– – 0.01% 144
2020
Q4 		$449K Hold
11,234
– – 0.01% 130
2020
Q3 		$640K Sell
11,234
-591
-5% -$41.7K 0.02% 132
2020
Q2 		$873K Buy
+11,825
New +$766K 0.02% 131

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Artal Group's CDTX Position: Q1 2023 in Review

Artal Group sold out of Cidara Therapeutics (CDTX) in Q1 2023, closing a stake of 11,234 shares — an estimated $170K sold.

Artal Group first reported a position in CDTX in Q2 2020 and held it in 11 quarters. The position peaked at $873K in Q2 2020. 54 funds tracked by Wall St. Rank hold CDTX as of Q1 2023.

  • Artal Group reported no remaining Cidara Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Artal Group sold 11,234 Cidara Therapeutics shares in Q1 2023, an estimated $170K.
  • Artal Group first reported a position in Cidara Therapeutics in Q2 2020 and held it in 11 quarters.
  • Artal Group's Cidara Therapeutics position peaked at $873K in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2023.

Based on Artal Group's 13F filing for Q1 2023, filed 12 May 2023.